A Brief Note on Drug Safety Surveillance

Abstract

*Correspondence to: Mounika Rani Gude, Department of Pharmacy, Global College of Pharmacy, Hyderabad, India, E-mail: monirani97 @gmail.com Received: July 7, 2021, Accepted: July 21, 2021, Published: July 28, 2021 Citation: Gude MR (2021) A Brief Note on Drug Safety Surveillance. J. Pharamacovigil. 9:326. doi-10.35248/2329-6887.21.9.326. Copyright: © 2021 Gude MR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Pharmacovigilance is like a sunshade to describe the processes for monitoring and evaluating ADRs and it is a key component of effective drug regulation systems, clinical practice and public health programmes. The number of Adverse Drug Reactions (ADRs) reported resulted in an increase in the volume of data handled, and to understand the pharmacovigilance, a high level of expertise is required to rapidly detect drug risks as well as to defend the product against an inappropriate removal. This would consider litigious and important drug safety issues that have the potential to affect public health adversely beyond national boundaries. Recently, pharmacovigilance has been confined, mainly to detect adverse drug events that were previously either unknown or poorly understood. Today many pharmacovigilance centers are working for drug safety monitoring in this global pitch, however, at the turn of the millennium pharmacovigilance faces major challenges in aspect of better safety and monitoring of drugs [1].